Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MLYS
MINERALYS THERAPEUTICS, INC.
NASDAQ
$25.65
▼ DOWN 0.39% (-0.10)

KEY STATISTICS

Market Cap$2.26 B
52w High$47.65
52w Low$14.53
Dividend Yield—
Frequency—
P/E-6.05
Volume699.84K
Shares Out.88.16M

COMPANY

LEADERSHIP

Jon Congleton
CHIEF EXECUTIVE
Jon Congleton

COMPENSATION 2026

Salary$636,500
Stock Awards$0
Incentive Plan Pay$472,601
All Other Comp.$0
Total$5,544,727

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 10, 2023
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
76

PRICE TARGET

Target High$56.00
Target Low$30.00
Target Median$43.00
Target Consensus$43.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.—
NOV
9
MON

PRICE

$25.65 ▼ DOWN 0.39% (−$0.10)
$25.80$26.00$26.209:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM25.65

About Mineralys Therapeutics, Inc.

https://mineralystx.com ↗

Mineralys Therapeutics, Inc., founded in 2019 in Radnor, PA, is a clinical-stage biopharmaceutical company developing lorundrostat, an oral, selective aldosterone synthase inhibitor for resistant hypertension and cardiovascular diseases.

INDUSTRY

Biotechnology

A PRODUCT MINERALYS THERAPEUTICS, INC. IS KNOWN FOR

Lorundrostat
Lorundrostat

Lorundrostat, a highly selective oral aldosterone synthase inhibitor in late-stage development by Mineralys Therapeutics, aims to treat resistant hypertension, chronic kidney disease, and sleep apnea, with positive Phase 3 trial results.

COMPETITORS

COMPETITOR
ALNY COMPARE
ARWR COMPARE
AZN COMPARE
IONS COMPARE
JNJ COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
130
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.67% · 2.9M
VTS.AX
0.00% · 2.0M
XSU.TO
0.05% · 1.5M
SCHA
0.03% · 303.1K
DFAS
0.03% · 156.0K
LABU
0.47% · 117.2K
SBIO
1.12% · 103.3K
FESM
0.03% · 73.9K
XRS2.DE
0.05% · 52.8K
RSSL
0.05% · 27.4K
BBSC
0.05% · 15.8K
BBC
0.66% · 13.2K
OP
OPTZ
0.19% · 12.6K
PRFZ
0.01% · 7.9K
HELX
0.44% · 5.4K
TILT
0.00% · 3.8K
ACSG
0.28% · 3.5K
BIB
0.07% · 2.8K
BKSE
0.07% · 2.5K
STXK
0.07% · 2.4K
ESSC
0.14% · 2.0K
RFLR
0.05% · 1.9K
VETS
0.14% · 1.4K
AVSC
0.00% · 466
USUE.DE
0.00% · 277
RESM
0.05% · 126

INSTITUTIONAL OWNERSHIP

SHARES OWNED
63.85%
HOLDERS
294
TOP 12 OF 294 · RANKED BY POSITION SIZE
Catalys Pacific, LLC
8.9M sh · $337.63M
Ra Capital Management, L.P.
7.7M sh · $207.55M
Samsara Biocapital, LLC
6.3M sh · $237.5M
Blackrock, Inc.
5.9M sh · $158.83M
Fmr LLC
5.1M sh · $183.54M
State Street Corp
4.1M sh · $111.74M
Deerfield Management Company, L.P. (Series C)
4.0M sh · $106.79M
Wellington Management Group Llp
3.4M sh · $91M
Vanguard Group Inc
3.4M sh · $121.68M
Caligan Partners LP
2.8M sh · $75.11M
Laurion Capital Management LP
2.5M sh · $67.62M
Capital International Investors
2.4M sh · $90.76M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Rodman David Malcom
Sale · 2.2K shares
2026-08-10
★
OFFICER: CHIEF MEDICAL OFFICER
Ferguson James J. III
Purchase · 135.0K shares
2026-08-10
★
OFFICER: CHIEF MEDICAL OFFICER
Ferguson James J. III
Purchase · 102.4K shares
2026-08-10
★
OFFICER
Ferguson James J. III
— · —
2026-08-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 1
HOLD 1
6 GRADES IN THE LAST 12 MONTHS
B of A Securities BUY Stifel BUY HC Wainwright & Co. BUY Wells Fargo OVERWEIGHT Goldman Sachs BUY Jefferies HOLD

SECTORS PEERS

PEERPRICE
SRRK$56.50COMPARE
ADPT$25.99COMPARE
IDYA$39.67COMPARE
BEAM$29.76COMPARE
ZLAB$26.01COMPARE
AGIO$33.09COMPARE
RXRX$3.50COMPARE